Bevacizumab Brand Name
Bevacizumab is marketed under the brand name Avastin®, with FDA-approved biosimilars including Avzivi® (bevacizumab-tnjn). 1, 2
Primary Brand Name
- Avastin® is the original brand name for bevacizumab, manufactured by Genentech/Roche 1, 3, 4
- This is a recombinant humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF) 1, 4
FDA-Approved Biosimilars
- Avzivi® (bevacizumab-tnjn) is an FDA-approved biosimilar manufactured by Bio-Thera Solutions, Ltd. 2
- The NCCN guidelines explicitly state that FDA-approved biosimilars may be substituted for bevacizumab wherever the therapy is recommended 1
Clinical Context
Bevacizumab/Avastin has FDA approval for intravenous use in multiple oncologic indications including:
- Metastatic colorectal cancer 1
- Advanced nonsquamous non-small cell lung cancer 1, 5
- Metastatic renal cell carcinoma 1, 6
- Metastatic breast cancer 1, 7
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer 3, 7
- Hepatocellular carcinoma (in combination with atezolizumab) 1
The drug is also used off-label for intravitreal injection in neovascular age-related macular degeneration, though this is not its FDA-approved indication 1, 8